 Robert Kramer
Concepts (429)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Foreign Bodies | 14 | 2025 | 107 | 3.610 |
Why?
| | Endoscopy, Gastrointestinal | 14 | 2025 | 237 | 2.800 |
Why?
| | Esophagoscopy | 10 | 2025 | 221 | 1.810 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 5 | 2024 | 219 | 1.740 |
Why?
| | Esophagus | 10 | 2019 | 261 | 1.560 |
Why?
| | Esophageal Stenosis | 6 | 2019 | 57 | 1.460 |
Why?
| | Electric Power Supplies | 8 | 2025 | 52 | 1.400 |
Why?
| | Dilatation | 3 | 2019 | 72 | 1.200 |
Why?
| | Gastroenterology | 8 | 2023 | 189 | 1.180 |
Why?
| | Gastroesophageal Reflux | 3 | 2023 | 236 | 1.160 |
Why?
| | Methyl Parathion | 6 | 2012 | 6 | 1.010 |
Why?
| | Eosinophilic Esophagitis | 8 | 2019 | 330 | 0.990 |
Why?
| | Amphotericin B | 5 | 2010 | 37 | 0.970 |
Why?
| | Vomiting | 3 | 2024 | 130 | 0.940 |
Why?
| | Insecticides | 5 | 2012 | 42 | 0.920 |
Why?
| | Esophageal Diseases | 2 | 2019 | 30 | 0.920 |
Why?
| | Catheterization | 4 | 2019 | 183 | 0.920 |
Why?
| | Polyenes | 3 | 2010 | 16 | 0.890 |
Why?
| | Superior Mesenteric Artery Syndrome | 1 | 2024 | 8 | 0.850 |
Why?
| | Patient Positioning | 1 | 2024 | 70 | 0.830 |
Why?
| | Pediatrics | 8 | 2018 | 1114 | 0.830 |
Why?
| | Child | 43 | 2025 | 22633 | 0.820 |
Why?
| | Gastrointestinal Diseases | 3 | 2017 | 216 | 0.820 |
Why?
| | Duodenoscopes | 2 | 2022 | 7 | 0.810 |
Why?
| | Abdominal Pain | 3 | 2024 | 146 | 0.800 |
Why?
| | Gastroenterologists | 1 | 2023 | 21 | 0.800 |
Why?
| | Quality Improvement | 6 | 2022 | 1289 | 0.760 |
Why?
| | Obesity, Morbid | 3 | 2023 | 281 | 0.740 |
Why?
| | Laparoscopy | 2 | 2023 | 475 | 0.690 |
Why?
| | Ketorolac | 1 | 2021 | 30 | 0.690 |
Why?
| | Bariatric Surgery | 2 | 2023 | 242 | 0.680 |
Why?
| | Clinical Competence | 4 | 2018 | 1244 | 0.680 |
Why?
| | Child, Preschool | 26 | 2025 | 11787 | 0.680 |
Why?
| | Endoscopy | 4 | 2021 | 316 | 0.670 |
Why?
| | Magnets | 2 | 2018 | 21 | 0.660 |
Why?
| | Intestine, Small | 2 | 2018 | 166 | 0.640 |
Why?
| | Pancreatitis | 1 | 2021 | 145 | 0.640 |
Why?
| | Postoperative Complications | 7 | 2025 | 2919 | 0.630 |
Why?
| | Retrospective Studies | 21 | 2024 | 17066 | 0.620 |
Why?
| | Digestive System | 2 | 2020 | 28 | 0.610 |
Why?
| | Quarantine | 1 | 2020 | 31 | 0.610 |
Why?
| | Fever | 1 | 2021 | 311 | 0.590 |
Why?
| | Colonoscopy | 3 | 2022 | 261 | 0.590 |
Why?
| | Endoscopy, Digestive System | 3 | 2025 | 140 | 0.590 |
Why?
| | Pediatric Obesity | 2 | 2023 | 637 | 0.580 |
Why?
| | Single-Balloon Enteroscopy | 1 | 2018 | 4 | 0.580 |
Why?
| | Antifungal Agents | 3 | 2009 | 149 | 0.560 |
Why?
| | Capsule Endoscopy | 3 | 2017 | 25 | 0.550 |
Why?
| | Esophageal Fistula | 2 | 2016 | 21 | 0.550 |
Why?
| | Bile Duct Diseases | 1 | 2018 | 13 | 0.550 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2025 | 136 | 0.550 |
Why?
| | Vascular Fistula | 2 | 2016 | 22 | 0.550 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 609 | 0.540 |
Why?
| | Self Expandable Metallic Stents | 1 | 2018 | 17 | 0.540 |
Why?
| | Anesthesia | 2 | 2024 | 258 | 0.540 |
Why?
| | Adolescent | 28 | 2025 | 22428 | 0.530 |
Why?
| | Humans | 72 | 2025 | 144759 | 0.520 |
Why?
| | Patient Safety | 2 | 2018 | 347 | 0.500 |
Why?
| | Infant | 17 | 2024 | 10034 | 0.500 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 357 | 0.490 |
Why?
| | Esophageal pH Monitoring | 1 | 2016 | 22 | 0.490 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 865 | 0.480 |
Why?
| | Electric Impedance | 1 | 2016 | 111 | 0.470 |
Why?
| | Algorithms | 4 | 2025 | 1837 | 0.470 |
Why?
| | Stomach | 2 | 2020 | 109 | 0.460 |
Why?
| | Duodenum | 1 | 2014 | 77 | 0.420 |
Why?
| | Mucous Membrane | 1 | 2014 | 127 | 0.410 |
Why?
| | Chronic Pain | 1 | 2018 | 290 | 0.410 |
Why?
| | Checklist | 1 | 2014 | 107 | 0.390 |
Why?
| | Female | 44 | 2025 | 78271 | 0.390 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 557 | 0.390 |
Why?
| | Male | 40 | 2025 | 72315 | 0.380 |
Why?
| | Hospitalization | 2 | 2021 | 2433 | 0.380 |
Why?
| | Cytochrome P-450 Enzyme System | 6 | 2012 | 162 | 0.360 |
Why?
| | Eating | 6 | 2021 | 389 | 0.340 |
Why?
| | Operative Time | 2 | 2024 | 175 | 0.340 |
Why?
| | Zona Glomerulosa | 3 | 2000 | 3 | 0.340 |
Why?
| | Esophageal Motility Disorders | 1 | 2011 | 29 | 0.330 |
Why?
| | Spectrum Analysis, Raman | 1 | 2010 | 41 | 0.320 |
Why?
| | Angiotensin II | 3 | 2000 | 97 | 0.320 |
Why?
| | Caustics | 1 | 2010 | 6 | 0.310 |
Why?
| | Salicylic Acid | 1 | 2010 | 10 | 0.310 |
Why?
| | Artifacts | 1 | 2010 | 139 | 0.310 |
Why?
| | Candida albicans | 2 | 2007 | 61 | 0.310 |
Why?
| | Burns, Chemical | 1 | 2010 | 32 | 0.310 |
Why?
| | Food | 1 | 2011 | 149 | 0.300 |
Why?
| | Jejunal Diseases | 1 | 2009 | 6 | 0.300 |
Why?
| | Dermatologic Agents | 1 | 2010 | 68 | 0.300 |
Why?
| | Drug Contamination | 1 | 2009 | 52 | 0.290 |
Why?
| | Cholinesterase Inhibitors | 4 | 2003 | 46 | 0.280 |
Why?
| | Fluorescence | 1 | 2009 | 161 | 0.280 |
Why?
| | Gastrostomy | 3 | 2018 | 130 | 0.280 |
Why?
| | Cholinesterases | 3 | 2002 | 9 | 0.270 |
Why?
| | Common Bile Duct | 1 | 2007 | 14 | 0.270 |
Why?
| | Hemorrhage | 3 | 2014 | 809 | 0.270 |
Why?
| | Treatment Outcome | 9 | 2024 | 11679 | 0.260 |
Why?
| | Drugs, Generic | 1 | 2007 | 27 | 0.260 |
Why?
| | Candidiasis | 1 | 2007 | 64 | 0.260 |
Why?
| | Creatinine | 2 | 2022 | 506 | 0.260 |
Why?
| | Aldosterone | 2 | 2000 | 43 | 0.260 |
Why?
| | Fluoroscopy | 3 | 2018 | 176 | 0.230 |
Why?
| | Stents | 1 | 2010 | 556 | 0.230 |
Why?
| | Prospective Studies | 6 | 2025 | 7990 | 0.230 |
Why?
| | Calcium | 6 | 2003 | 1183 | 0.230 |
Why?
| | Prone Position | 1 | 2024 | 24 | 0.220 |
Why?
| | Supine Position | 1 | 2024 | 37 | 0.220 |
Why?
| | Biopsy | 4 | 2019 | 1075 | 0.210 |
Why?
| | Gastrectomy | 2 | 2023 | 161 | 0.210 |
Why?
| | Learning Curve | 1 | 2024 | 70 | 0.210 |
Why?
| | Obesity | 3 | 2009 | 3077 | 0.210 |
Why?
| | Vascular System Injuries | 1 | 2025 | 77 | 0.210 |
Why?
| | Nausea | 1 | 2024 | 111 | 0.200 |
Why?
| | Hospitals, Pediatric | 2 | 2021 | 556 | 0.200 |
Why?
| | Anastomotic Leak | 1 | 2023 | 44 | 0.200 |
Why?
| | Syndrome | 1 | 2024 | 380 | 0.200 |
Why?
| | Rats, Sprague-Dawley | 7 | 2012 | 2527 | 0.190 |
Why?
| | Constriction, Pathologic | 1 | 2023 | 248 | 0.190 |
Why?
| | Rats | 15 | 2012 | 5597 | 0.190 |
Why?
| | Patient Care Team | 3 | 2018 | 689 | 0.180 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2012 | 594 | 0.180 |
Why?
| | Cannabinoids | 1 | 2024 | 182 | 0.180 |
Why?
| | Patient Satisfaction | 2 | 2017 | 704 | 0.180 |
Why?
| | Paracentesis | 1 | 2001 | 16 | 0.180 |
Why?
| | Palliative Care | 1 | 2010 | 1002 | 0.170 |
Why?
| | Consensus | 5 | 2022 | 488 | 0.170 |
Why?
| | Marijuana Abuse | 1 | 2024 | 211 | 0.170 |
Why?
| | Extracellular Space | 2 | 2000 | 120 | 0.170 |
Why?
| | Ascites | 1 | 2001 | 49 | 0.170 |
Why?
| | Pancreatic Ducts | 1 | 2021 | 81 | 0.170 |
Why?
| | Perfusion | 1 | 2022 | 250 | 0.160 |
Why?
| | Cohort Studies | 3 | 2018 | 5960 | 0.160 |
Why?
| | Goals | 1 | 2022 | 183 | 0.160 |
Why?
| | Risk Assessment | 3 | 2018 | 3671 | 0.160 |
Why?
| | Cardiopulmonary Bypass | 1 | 2022 | 221 | 0.160 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1907 | 0.150 |
Why?
| | Multiple Chemical Sensitivity | 1 | 1999 | 1 | 0.150 |
Why?
| | Equipment Contamination | 1 | 2020 | 71 | 0.150 |
Why?
| | Somatoform Disorders | 1 | 1999 | 35 | 0.150 |
Why?
| | Emergencies | 2 | 2011 | 175 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 288 | 0.150 |
Why?
| | Alarmins | 1 | 2019 | 27 | 0.150 |
Why?
| | Kinetics | 5 | 2012 | 1627 | 0.140 |
Why?
| | Alcohols | 1 | 1999 | 28 | 0.140 |
Why?
| | Informed Consent | 2 | 2017 | 198 | 0.140 |
Why?
| | Adverse Outcome Pathways | 1 | 2018 | 3 | 0.140 |
Why?
| | Disinfection | 1 | 2020 | 129 | 0.140 |
Why?
| | Tranexamic Acid | 1 | 2019 | 53 | 0.140 |
Why?
| | Play and Playthings | 1 | 2018 | 35 | 0.140 |
Why?
| | Testosterone | 4 | 2012 | 419 | 0.130 |
Why?
| | Esophageal Mucosa | 1 | 2018 | 22 | 0.130 |
Why?
| | Epidermolysis Bullosa | 1 | 2018 | 68 | 0.130 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1489 | 0.130 |
Why?
| | Risk Factors | 2 | 2022 | 10779 | 0.130 |
Why?
| | Virtual Reality | 1 | 2019 | 77 | 0.130 |
Why?
| | Age Factors | 2 | 2016 | 3333 | 0.130 |
Why?
| | Microsomes, Liver | 5 | 2012 | 85 | 0.130 |
Why?
| | Seizures | 2 | 1999 | 460 | 0.130 |
Why?
| | Intestinal Mucosa | 2 | 2015 | 676 | 0.120 |
Why?
| | Operating Rooms | 1 | 2018 | 146 | 0.120 |
Why?
| | Intestines | 2 | 2012 | 358 | 0.120 |
Why?
| | Disease Outbreaks | 1 | 2020 | 422 | 0.120 |
Why?
| | Gastritis | 1 | 2017 | 115 | 0.120 |
Why?
| | Enteritis | 1 | 2017 | 103 | 0.120 |
Why?
| | Creatine Kinase, MB Form | 1 | 2015 | 6 | 0.120 |
Why?
| | Angiography | 1 | 2016 | 208 | 0.120 |
Why?
| | Animals | 23 | 2019 | 38058 | 0.120 |
Why?
| | Ischemic Preconditioning | 1 | 2015 | 47 | 0.110 |
Why?
| | Administration, Cutaneous | 4 | 2003 | 125 | 0.110 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.110 |
Why?
| | Eosinophilia | 1 | 2017 | 221 | 0.110 |
Why?
| | Young Adult | 7 | 2025 | 14105 | 0.110 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2010 | 561 | 0.110 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2015 | 137 | 0.110 |
Why?
| | Stomach Diseases | 1 | 2014 | 20 | 0.110 |
Why?
| | Cathartics | 1 | 2014 | 15 | 0.110 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 335 | 0.110 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5408 | 0.100 |
Why?
| | Androstadienes | 1 | 2014 | 76 | 0.100 |
Why?
| | 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 2 | 2003 | 2 | 0.100 |
Why?
| | Colorado | 1 | 2024 | 4564 | 0.100 |
Why?
| | Linear Models | 1 | 2016 | 854 | 0.100 |
Why?
| | Burns | 1 | 2019 | 377 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 885 | 0.100 |
Why?
| | Anus Diseases | 1 | 2013 | 8 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2012 | 1560 | 0.100 |
Why?
| | Diltiazem | 1 | 1993 | 17 | 0.100 |
Why?
| | Drug Resistance | 1 | 2014 | 153 | 0.100 |
Why?
| | Time-to-Treatment | 1 | 2016 | 243 | 0.100 |
Why?
| | Endoscopes, Gastrointestinal | 1 | 2013 | 13 | 0.100 |
Why?
| | Failure to Thrive | 1 | 2013 | 28 | 0.100 |
Why?
| | Administration, Oral | 3 | 2014 | 847 | 0.100 |
Why?
| | Injections, Intravenous | 3 | 2002 | 200 | 0.100 |
Why?
| | Fistula | 1 | 2013 | 48 | 0.100 |
Why?
| | Pneumonia | 1 | 2019 | 631 | 0.100 |
Why?
| | Abscess | 1 | 2013 | 75 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2115 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2018 | 600 | 0.100 |
Why?
| | Mitochondria | 2 | 2019 | 984 | 0.100 |
Why?
| | Anal Canal | 1 | 2013 | 102 | 0.090 |
Why?
| | Potassium | 1 | 1993 | 152 | 0.090 |
Why?
| | Intestinal Perforation | 1 | 2012 | 44 | 0.090 |
Why?
| | Deglutition | 1 | 2012 | 72 | 0.090 |
Why?
| | Hydroxylation | 1 | 2012 | 49 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 189 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2017 | 780 | 0.090 |
Why?
| | Time Factors | 4 | 2019 | 7173 | 0.090 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2012 | 85 | 0.090 |
Why?
| | Preoperative Care | 1 | 2014 | 379 | 0.090 |
Why?
| | Oxidation-Reduction | 4 | 2012 | 1087 | 0.090 |
Why?
| | Sulfur | 1 | 2012 | 64 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 331 | 0.090 |
Why?
| | Monocytes | 2 | 2007 | 538 | 0.080 |
Why?
| | Celiac Disease | 1 | 2014 | 308 | 0.080 |
Why?
| | Isoenzymes | 1 | 2012 | 299 | 0.080 |
Why?
| | Dopamine | 2 | 2003 | 283 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2020 | 6429 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 474 | 0.080 |
Why?
| | Spectrophotometry | 2 | 2009 | 61 | 0.080 |
Why?
| | Triamcinolone | 1 | 2010 | 13 | 0.080 |
Why?
| | Spectrometry, Fluorescence | 1 | 2010 | 168 | 0.080 |
Why?
| | Enteral Nutrition | 2 | 2010 | 216 | 0.080 |
Why?
| | Injections, Intralesional | 1 | 2010 | 36 | 0.080 |
Why?
| | Esophageal Perforation | 1 | 2010 | 15 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2385 | 0.080 |
Why?
| | Colloids | 1 | 2010 | 61 | 0.080 |
Why?
| | Crohn Disease | 1 | 2013 | 260 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1539 | 0.070 |
Why?
| | Epilepsy | 2 | 1998 | 376 | 0.070 |
Why?
| | Incidence | 1 | 2016 | 2879 | 0.070 |
Why?
| | Prednisolone | 1 | 2009 | 66 | 0.070 |
Why?
| | Trachea | 1 | 2011 | 261 | 0.070 |
Why?
| | Poisoning | 1 | 2010 | 119 | 0.070 |
Why?
| | Esophagitis | 1 | 2009 | 66 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2310 | 0.070 |
Why?
| | Microbial Sensitivity Tests | 2 | 2007 | 370 | 0.070 |
Why?
| | Mass Spectrometry | 1 | 2012 | 750 | 0.070 |
Why?
| | United States | 4 | 2023 | 15966 | 0.070 |
Why?
| | Sex Factors | 3 | 2013 | 2112 | 0.070 |
Why?
| | Liver | 8 | 2014 | 1887 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4557 | 0.070 |
Why?
| | Aorta | 1 | 2011 | 429 | 0.070 |
Why?
| | Deglutition Disorders | 1 | 2010 | 147 | 0.070 |
Why?
| | Cattle | 3 | 2000 | 1000 | 0.070 |
Why?
| | Logistic Models | 1 | 2013 | 2117 | 0.070 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2007 | 58 | 0.070 |
Why?
| | Stimulation, Chemical | 2 | 2000 | 53 | 0.070 |
Why?
| | Water | 1 | 2010 | 469 | 0.060 |
Why?
| | Receptors, Opioid, kappa | 2 | 2003 | 9 | 0.060 |
Why?
| | PC12 Cells | 2 | 2003 | 42 | 0.060 |
Why?
| | Body Weight | 5 | 2006 | 976 | 0.060 |
Why?
| | Status Epilepticus | 1 | 1987 | 56 | 0.060 |
Why?
| | Eosinophils | 1 | 2009 | 316 | 0.060 |
Why?
| | Models, Molecular | 1 | 2012 | 1618 | 0.060 |
Why?
| | Growth Hormone | 2 | 1978 | 92 | 0.060 |
Why?
| | Short Bowel Syndrome | 1 | 2006 | 27 | 0.060 |
Why?
| | Fatty Liver | 1 | 2009 | 251 | 0.060 |
Why?
| | Growth | 1 | 2006 | 49 | 0.060 |
Why?
| | Equipment Design | 1 | 2007 | 530 | 0.060 |
Why?
| | Adult | 11 | 2022 | 40449 | 0.060 |
Why?
| | Pentoxifylline | 1 | 2005 | 23 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2009 | 354 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1356 | 0.060 |
Why?
| | Pituitary Gland | 2 | 1975 | 148 | 0.050 |
Why?
| | Proteomics | 1 | 2012 | 1195 | 0.050 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1253 | 0.050 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 179 | 0.050 |
Why?
| | Brain | 4 | 2003 | 2933 | 0.050 |
Why?
| | Dietary Fats | 1 | 2006 | 314 | 0.050 |
Why?
| | Comorbidity | 1 | 2009 | 1658 | 0.050 |
Why?
| | Cell Line | 2 | 2007 | 2882 | 0.050 |
Why?
| | Electroencephalography | 3 | 1999 | 532 | 0.050 |
Why?
| | Paraoxon | 1 | 2003 | 2 | 0.050 |
Why?
| | Acetylcholinesterase | 1 | 2003 | 8 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2000 | 4154 | 0.050 |
Why?
| | Cell Survival | 2 | 1999 | 1098 | 0.050 |
Why?
| | Receptors, Muscarinic | 1 | 2003 | 20 | 0.050 |
Why?
| | Estradiol | 2 | 1978 | 533 | 0.050 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2003 | 123 | 0.050 |
Why?
| | Naltrexone | 1 | 2003 | 117 | 0.050 |
Why?
| | Drug Administration Routes | 1 | 2002 | 42 | 0.050 |
Why?
| | Cecum | 1 | 2022 | 37 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2847 | 0.040 |
Why?
| | Mathematics | 1 | 2002 | 100 | 0.040 |
Why?
| | Inflammation | 1 | 2013 | 2878 | 0.040 |
Why?
| | Endosonography | 1 | 2023 | 157 | 0.040 |
Why?
| | Plasma Volume | 1 | 2001 | 20 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2002 | 327 | 0.040 |
Why?
| | Punctures | 1 | 2001 | 40 | 0.040 |
Why?
| | Area Under Curve | 1 | 2002 | 330 | 0.040 |
Why?
| | Pharmaceutical Preparations | 3 | 1978 | 170 | 0.040 |
Why?
| | Disease Management | 2 | 2019 | 645 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2003 | 1306 | 0.040 |
Why?
| | Behavior | 1 | 2001 | 91 | 0.040 |
Why?
| | Needles | 1 | 2001 | 62 | 0.040 |
Why?
| | Ileum | 1 | 2022 | 111 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2003 | 2027 | 0.040 |
Why?
| | Anions | 1 | 2000 | 31 | 0.040 |
Why?
| | Drainage | 1 | 2001 | 185 | 0.040 |
Why?
| | Delphi Technique | 1 | 2022 | 329 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3863 | 0.040 |
Why?
| | Nasal Provocation Tests | 1 | 1999 | 3 | 0.040 |
Why?
| | Calmodulin | 1 | 1999 | 70 | 0.040 |
Why?
| | Safety | 1 | 2001 | 356 | 0.040 |
Why?
| | Personality Inventory | 1 | 1999 | 134 | 0.040 |
Why?
| | Administration, Topical | 1 | 2019 | 150 | 0.040 |
Why?
| | Odorants | 1 | 1999 | 116 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 1999 | 160 | 0.030 |
Why?
| | Adrenal Glands | 2 | 1976 | 77 | 0.030 |
Why?
| | Video Recording | 1 | 1999 | 212 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 266 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2608 | 0.030 |
Why?
| | DNA, Mitochondrial | 1 | 2019 | 211 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2017 | 79 | 0.030 |
Why?
| | Temporal Lobe | 1 | 1998 | 104 | 0.030 |
Why?
| | Contraindications, Procedure | 1 | 2017 | 12 | 0.030 |
Why?
| | Cell Division | 1 | 1999 | 766 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 1987 | 2730 | 0.030 |
Why?
| | Morphine Derivatives | 2 | 1975 | 19 | 0.030 |
Why?
| | Intracellular Fluid | 2 | 2003 | 25 | 0.030 |
Why?
| | Phenytoin | 1 | 1996 | 21 | 0.030 |
Why?
| | Castration | 4 | 1978 | 15 | 0.030 |
Why?
| | Treatment Refusal | 1 | 2017 | 98 | 0.030 |
Why?
| | Mice | 2 | 2019 | 18339 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 6048 | 0.030 |
Why?
| | North America | 1 | 2017 | 310 | 0.030 |
Why?
| | Prodrugs | 1 | 1996 | 52 | 0.030 |
Why?
| | Interleukin-1 | 1 | 1999 | 961 | 0.030 |
Why?
| | Heart Valves | 1 | 2015 | 43 | 0.030 |
Why?
| | Steroid Hydroxylases | 1 | 1975 | 20 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 88 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2015 | 312 | 0.030 |
Why?
| | Laxatives | 1 | 2014 | 21 | 0.030 |
Why?
| | Phosphorylation | 1 | 1999 | 1732 | 0.030 |
Why?
| | Fluticasone | 1 | 2014 | 53 | 0.030 |
Why?
| | Anticonvulsants | 1 | 1996 | 235 | 0.030 |
Why?
| | Pruritus Ani | 1 | 2013 | 2 | 0.030 |
Why?
| | Suppuration | 1 | 2013 | 9 | 0.030 |
Why?
| | Fissure in Ano | 1 | 2013 | 4 | 0.030 |
Why?
| | Coronary Artery Bypass | 1 | 2015 | 268 | 0.020 |
Why?
| | Remission Induction | 1 | 2014 | 307 | 0.020 |
Why?
| | Hypophysectomy | 4 | 1978 | 15 | 0.020 |
Why?
| | Neodymium | 1 | 2012 | 1 | 0.020 |
Why?
| | Reperfusion Injury | 1 | 2015 | 300 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2014 | 2029 | 0.020 |
Why?
| | Organ Size | 5 | 1978 | 463 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1999 | 935 | 0.020 |
Why?
| | Fecal Incontinence | 1 | 2013 | 91 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 779 | 0.020 |
Why?
| | Drug Interactions | 1 | 1993 | 398 | 0.020 |
Why?
| | Nutrition Assessment | 1 | 2011 | 92 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 633 | 0.020 |
Why?
| | Brain Injuries | 1 | 1996 | 507 | 0.020 |
Why?
| | Dantrolene | 1 | 1988 | 5 | 0.020 |
Why?
| | Gallic Acid | 1 | 1988 | 9 | 0.020 |
Why?
| | Cytosol | 1 | 1988 | 227 | 0.020 |
Why?
| | Pain | 1 | 2013 | 779 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5992 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1782 | 0.020 |
Why?
| | Carbon Radioisotopes | 1 | 2006 | 29 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2015 | 8265 | 0.020 |
Why?
| | Palmitates | 1 | 2006 | 21 | 0.020 |
Why?
| | Breeding | 1 | 2006 | 63 | 0.020 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 56 | 0.010 |
Why?
| | Aniline Hydroxylase | 2 | 1975 | 2 | 0.010 |
Why?
| | Ethylmorphine-N-Demethylase | 2 | 1975 | 2 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2925 | 0.010 |
Why?
| | Intestinal Absorption | 1 | 2006 | 103 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2006 | 151 | 0.010 |
Why?
| | Body Height | 1 | 2006 | 202 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2006 | 415 | 0.010 |
Why?
| | In Vitro Techniques | 3 | 2003 | 1047 | 0.010 |
Why?
| | Testis | 2 | 1975 | 163 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 2006 | 242 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4271 | 0.010 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 2003 | 18 | 0.010 |
Why?
| | Triglycerides | 1 | 2006 | 520 | 0.010 |
Why?
| | Rabbits | 1 | 2005 | 648 | 0.010 |
Why?
| | Quinuclidinyl Benzilate | 1 | 2003 | 3 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2003 | 38 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 60 | 0.010 |
Why?
| | Radioligand Assay | 1 | 2003 | 37 | 0.010 |
Why?
| | Autoradiography | 1 | 2003 | 64 | 0.010 |
Why?
| | Tritium | 1 | 2003 | 68 | 0.010 |
Why?
| | Neostriatum | 1 | 2003 | 37 | 0.010 |
Why?
| | Chelating Agents | 1 | 2003 | 71 | 0.010 |
Why?
| | Culture Media | 1 | 2003 | 161 | 0.010 |
Why?
| | Brain Stem | 1 | 2003 | 95 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2003 | 179 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2006 | 652 | 0.010 |
Why?
| | Thalamus | 1 | 2003 | 125 | 0.010 |
Why?
| | Narcotic Antagonists | 1 | 2003 | 205 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2006 | 790 | 0.010 |
Why?
| | Thapsigargin | 1 | 1999 | 20 | 0.010 |
Why?
| | Aniline Compounds | 2 | 1978 | 119 | 0.010 |
Why?
| | Calcimycin | 1 | 1999 | 36 | 0.010 |
Why?
| | Middle Aged | 3 | 2015 | 35875 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2003 | 464 | 0.010 |
Why?
| | Memory | 1 | 2001 | 295 | 0.010 |
Why?
| | Aged | 2 | 2015 | 25913 | 0.010 |
Why?
| | Ethylmorphine | 1 | 1978 | 1 | 0.010 |
Why?
| | Imidazoles | 1 | 1999 | 254 | 0.010 |
Why?
| | Discriminant Analysis | 1 | 1998 | 36 | 0.010 |
Why?
| | Seizures, Febrile | 1 | 1998 | 22 | 0.010 |
Why?
| | Phenotype | 1 | 2006 | 3162 | 0.010 |
Why?
| | Thyroxine | 1 | 1978 | 64 | 0.010 |
Why?
| | Learning | 1 | 2001 | 452 | 0.010 |
Why?
| | Hippocampus | 1 | 2003 | 965 | 0.010 |
Why?
| | Motor Activity | 1 | 2001 | 721 | 0.010 |
Why?
| | Functional Laterality | 1 | 1998 | 241 | 0.010 |
Why?
| | Benzene Derivatives | 1 | 1976 | 10 | 0.010 |
Why?
| | Microsomes | 1 | 1976 | 33 | 0.010 |
Why?
| | Benzene | 1 | 1976 | 18 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 824 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 1996 | 141 | 0.010 |
Why?
| | Naphthalenes | 1 | 1976 | 56 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2006 | 1795 | 0.010 |
Why?
| | Pregnenolone | 1 | 1975 | 3 | 0.010 |
Why?
| | Vitamin A Deficiency | 1 | 1975 | 26 | 0.010 |
Why?
| | Prolactin | 1 | 1975 | 89 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1998 | 630 | 0.010 |
Why?
| | Adrenocorticotropic Hormone | 1 | 1975 | 147 | 0.010 |
Why?
| | Corticosterone | 1 | 1975 | 244 | 0.010 |
Why?
| | Ovary | 1 | 1975 | 228 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1975 | 478 | 0.010 |
Why?
| | Prognosis | 1 | 1998 | 4282 | 0.000 |
Why?
| | Mixed Function Oxygenases | 2 | 1978 | 49 | 0.000 |
Why?
| | Thyroidectomy | 1 | 1978 | 91 | 0.000 |
Why?
| | Guinea Pigs | 1 | 1976 | 159 | 0.000 |
Why?
| | Proteins | 1 | 1975 | 1021 | 0.000 |
Why?
|
|
Kramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|